STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 - Reports Early Adoption Momentum in Mexico
MWN-AI** Summary
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in dermatological technologies, showcased its XTRAC® excimer laser and TheraclearX® acne therapy system at the TeraCILAD 2025 in Mexico City from November 19-22, 2025. The company reported significant growth in early adoption of TheraclearX®, with expectations of over 12 recurring accounts in Mexico by year-end 2025. This reflects a rising interest among dermatologists in non-drug acne therapies, enhancing patient treatment options.
At TeraCILAD, renowned dermatologist Dr. Melissa Lomeli, who is the first TheraclearX® user in Mexico, shared compelling clinical insights, stating that acne can improve significantly after just one session. This presentation highlighted the efficacy of the TheraclearX® system, underscoring a shift in acne treatment protocols. Additionally, Dr. Henry Lim discussed the advantages of the XTRAC® 308 nm excimer laser in treating skin disorders such as psoriasis and vitiligo.
The event was a major platform for STRATA to engage with top dermatology professionals, showcasing the impressive treatment outcomes provided by its devices. COO Shmuel Gov noted the enthusiasm for both XTRAC® and TheraclearX®, with dermatologists keen on integrating innovative, non-systemic options into their practice. STRATA's strategic goal is to cultivate sustainable revenue streams, with potential revenues estimated at around $30,000 annually per clinic from the adoption of these technologies.
As STRATA amplifies its presence in Latin America, the participation in TeraCILAD 2025 reaffirms the company’s commitment to delivering advanced dermatologic solutions that enhance patient care and support dermatologists with unique, effective treatment modalities.
MWN-AI** Analysis
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) showcased promising advancements at the TeraCILAD 2025 congress, demonstrating its XTRAC® excimer laser and TheraclearX® acne therapy system. The company's strategic focus on expanding its presence in the Ibero-Latin American dermatology market is reflected in its forecast of over 12 recurring TheraclearX® accounts in Mexico by year-end 2025. This early adoption indicates strong demand for non-pharmaceutical acne treatment options among dermatologists, potentially positioning STRATA well within this niche market.
The reception of both XTRAC® and TheraclearX® at TeraCILAD suggests a growing validation of device-based therapies in dermatologic practice. Dr. Melissa Lomeli's session highlighted the impressive results achievable with TheraclearX®, positioning it potentially as a game-changer in the treatment of mild to moderate acne. With increasing clinical engagement, STRATA might leverage this momentum to boost its brand equity and drive sales. As CEO Dolev Rafaeli mentioned, past experiences with XTRAC installations indicate potential annual revenues of around $30,000 per clinic, underscoring the financial upside of this strategy.
Investors should closely monitor these developments, as the metrics of adoption and revenue generation will be critical indicators of STRATA's growth trajectory. The dermatology sector shows a rising trend towards effective, non-invasive treatment modalities, which may favor STRATA's technological innovations. While early-stage revenues may be uncertain, the strategic intentions expressed through their clinical engagements and partnerships suggest a groundwork for long-term success.
In summary, STRATA's proactive engagement in Mexico could serve as an attractive opportunity for investors, especially as the company aims to solidify its presence in the expanding dermatology market across Latin America. However, caution should be exercised given the inherent uncertainties in market expansion and revenue realization.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico , reflecting growing adoption of this innovative acne treatment modality by dermatologists in the region.
Key Highlights
- STRATA showcased XTRAC® , the leading targeted UVB excimer laser for psoriasis, vitiligo, and other skin conditions, and TheraclearX® , its photopneumatic acne therapy system now commercially available in Mexico.
- By year-end 2025, STRATA anticipates more than a dozen recurring TheraclearX® accounts in Mexico, demonstrating strong dermatology interest in this non-drug, device-based acne therapy.
- TeraCILAD 2025, organized every two years by the Latin American College of Dermatology, provides a platform to engage Ibero-Latin American dermatology leaders, present clinical outcomes, and highlight the efficacy of STRATA’s technologies for improving patient care.
Conference Presentations & Clinical Insights
At the conference, Dr. Melissa Lomeli, a leading dermatology provider and the first TheraClearX® user in Mexico, shared her experience with the technology in a session titled, “ ThéraClearX: Rewriting the Protocol for the Treatment of Mild to Moderate Acne. ” During the presentation she told those in attendance, “What would happen if I told you that acne can improve in just one 20-minute session? It sounds too good to be true, right? Today, I’m going to show you why it is possible.”
Dr. Henry Lim, a global expert in inflammatory and autoimmune skin diseases, President of the International League of Dermatological Societies, former Chair of Dermatology at Henry Ford Health, and past AAD President, shared insights in his talk, “ XTRAC 308 nm Excimer Laser Therapy for Vitiligo, Psoriasis, and Atopic Dermatitis. ”
Market Context
At TeraCILAD 2025 — a premier dermatology congress in the Ibero-Latin American region — STRATA engaged with leading dermatologists to present the clinical performance and patient outcomes of its technologies. XTRAC® continues to be recognized for its precision and efficiency in treating inflammatory and autoimmune skin disorders, while TheraclearX® is gaining traction as an innovative, non-pharmaceutical solution for acne.
“We were very encouraged by the level of interest and engagement we saw at TeraCILAD, around both XTRAC and TheraClearX,” said Shmuel Gov, STRATA Chief Operating Officer, who attended the congress. “Dermatologists are clearly seeking effective, non-systemic treatment options they can integrate into routine clinical practice, and the feedback we received underscores the growing recognition of our technologies as valuable tools for improving patient outcomes.”
In Mexico, early commercial placements of TheraclearX® have already begun, and the Company expects over 12 recurring accounts by the end of 2025 . This adoption reflects dermatologists’ confidence in incorporating TheraclearX® into recurring patient treatment plans, contributing to STRATA’s goal of sustainable recurring revenue streams in the region.
CEO Dolev Rafaeli added, “While it is still early to estimate what will be the commercial value of each of these individual placements, time has shown with our XTRAC placements in other countries that when the partner clinic is fully developed, STRATA can realize upwards of $30,000 in annual revenue per clinic.”
Strategic Outlook
STRATA remains committed to expanding access to advanced dermatology solutions across Latin America and globally. The Company’s presence at TeraCILAD 2025 reinforces its strategy of engaging key opinion leaders, supporting dermatologists with innovative treatment options, and growing recurring revenue opportunities through device-based therapies.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC ® excimer laser, VTRAC ® lamp systems, and the TheraClear ® X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com .
Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ**
How does STRATA Skin Sciences Inc. SSKN plan to leverage the growing adoption of the TheraclearX® system in Mexico to enhance its market presence throughout Latin America?
What specific clinical outcomes were highlighted by Dr. Melissa Lomeli regarding the TheraclearX® treatment during TeraCILAD 2025, and how might these impact investor confidence in STRATA Skin Sciences Inc. SSKN?
In what ways does STRATA Skin Sciences Inc. SSKN intend to differentiate its XTRAC® laser therapy from competitors in the dermatology market following the positive reception at TeraCILAD 2025?
What revenue growth projections can investors expect from the anticipated recurring accounts of TheraclearX® in Mexico for STRATA Skin Sciences Inc. SSKN in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Strata Skin Sciences Inc. (NASDAQ: SSKN).
NASDAQ: SSKN
SSKN Trading
-23.2% G/L:
$0.2208 Last:
1,743,206 Volume:
$0.2848 Open:
